Clinical trial · no report yet · Phase 3
JADE
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- NCT06256588 ↗
- Recruiting
- GlaxoSmithKline
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Neoplasms, Head and Neck
- Interventions
- Dostarlimab; Placebo
- Arms
- Arm A: Dostarlimab · Experimental
- Arm B: Placebo · Placebo comparator
- Enrollment
- 864 (estimated)
- Primary outcomes
- Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- GlaxoSmithKline
- Start
- Mar 21, 2024
- Primary completion
- Jun 30, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06256588 · updated May 26, 2026
Publications
linked from the registry- Siu LL, Burtness B, Harrington K, Psyrri A, Saba NF, Tahara M, Carlson G, Dhar A, Grimshaw M, Hua L, Iadevaia R, Theti D, Vlahovic G, Machiels JP. JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. Future Oncol. 2026 Feb;22(3):313-320. doi: 10.1080/14796694.2026.2619653. Epub 2026 Jan 30. PubMed 41612885